Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.56. Xtant Medical shares last traded at $0.54, with a volume of 15,355 shares changing hands.
Analyst Ratings Changes
Separately, Craig Hallum set a $1.50 target price on Xtant Medical and gave the stock a "buy" rating in a research report on Friday, October 18th.
Get Our Latest Analysis on XTNT
Xtant Medical Price Performance
The company has a market cap of $69.86 million, a P/E ratio of -26.81 and a beta of 0.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.44 and a quick ratio of 1.01.
Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The medical device company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). Xtant Medical had a negative return on equity of 6.71% and a negative net margin of 3.00%. The business had revenue of $29.94 million for the quarter.
Hedge Funds Weigh In On Xtant Medical
Institutional investors have recently bought and sold shares of the business. Evernest Financial Advisors LLC bought a new stake in shares of Xtant Medical during the third quarter valued at approximately $27,000. Vanguard Group Inc. lifted its holdings in Xtant Medical by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company's stock worth $1,812,000 after buying an additional 48,319 shares in the last quarter. Finally, Juniper Investment Company LLC bought a new position in Xtant Medical in the 1st quarter valued at $408,000. Institutional investors own 69.33% of the company's stock.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Further Reading
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
